Vistagen Therapeutics, Inc.
Financial highlights
| Metric | FY 03/31/25 | FY 03/31/24 | FY 03/31/23 | FY 03/31/22 | FY 03/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $486,000 | $1.1M | -$227,000 | $1.1M | $1.1M |
| Research and development | $39.4M | $20.0M | $44.4M | $35.4M | $11.9M |
| Operating expenses | $56.5M | $34.1M | $59.0M | $48.9M | $19.0M |
| Operating income | -$56.0M | -$33.0M | -$59.3M | -$47.8M | -$17.9M |
| Pretax income | -$51.4M | -$29.4M | -$59.2M | -$47.8M | -$17.9M |
| Income tax expense | $7,000 | $4,000 | $6,000 | $3,400 | $2,600 |
| Net income | -$51.4M | -$29.4M | -$59.2M | -$47.8M | -$17.9M |
| Balance Sheet | |||||
| Cash and equivalents | $67.1M | $119.2M | $16.6M | $68.1M | $103.1M |
| Current assets | $82.1M | $120.7M | $17.5M | $71.0M | $104.1M |
| Total assets | $84.3M | $123.7M | $21.1M | $74.6M | $108.3M |
| Current liabilities | $12.6M | $5.1M | $4.6M | $5.8M | $4.2M |
| Total liabilities | $14.0M | $9.4M | $9.0M | $9.9M | $16.3M |
| Stockholders' equity | $70.4M | $114.3M | $12.1M | $64.7M | $92.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$42.1M | -$25.8M | -$49.7M | -$45.3M | -$12.1M |
| Depreciation and amortization | $150,000 | $127,000 | $130,000 | $153,500 | $117,600 |
| Stock-based compensation | $4.3M | $2.2M | $3.3M | $3.5M | $2.3M |
| Capital expenditure | $0 | $0 | $528,000 | $200,400 | $275,400 |
| Free cash flow | -$42.1M | -$25.8M | -$50.2M | -$45.5M | -$12.3M |
Shares outstanding 39.6M · Free float 42.7%
Annual filing data through FY ended March 31, 2025; float as of July 4, 2026.